Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Ao Qi Medical Technology Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single pending matter is assigned to examiner DAHLIN, HEATHER RAQUEL, who serves as the busiest examiner for the portfolio with 1 pending office action. The concentration of the portfolio is highly localized, as the data shows only 1 distinct examiner and 1 distinct art unit involved in current prosecution.
Practitioners should note the narrow focus of this portfolio. Having only 1 distinct art unit and 1 distinct examiner suggests that the current patent strategy is centered on a specific niche within Biotechnology & Pharmaceuticals. The fact that the busiest examiner handles this pending matter means that the outcome of this single application will significantly impact the portfolio's immediate trajectory.
The presence of this pending office action indicates a streamlined prosecution profile. This structure allows for a very specific interaction with the patent office, as all current activity is funneled through a single examiner. The reliance on 1 distinct examiner and 1 distinct art unit simplifies the administrative tracking for this specific portfolio at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259808 | POLYMORPHIC SUBSTANCE OF A-DECARBURIZATION-5alpha ANDROSTANE COMPOUND | DAHLIN, HEATHER RAQUEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259808 | POLYMORPHIC SUBSTANCE OF A-DECARBURIZATION-5alpha ANDROSTANE COMPOUND | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259808 | POLYMORPHIC SUBSTANCE OF A-DECARBURIZATION-5alpha ANDROSTANE COMPOUND | DAHLIN, HEATHER RAQUEL | 1629 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Ao Qi Medical Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Heather Raquel Dahlin has the most, with 1 of Shanghai Ao Qi Medical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
